Submitted by web@researchtop... on Fri, 05/25/2012 - 16:33  
    Submitted by web@researchtop... on Fri, 05/25/2012 - 16:31  
    Submitted by web@researchtop... on Fri, 05/25/2012 - 16:29  
    Submitted by web@researchtop... on Fri, 05/25/2012 - 16:27  
    Submitted by web@researchtop... on Fri, 05/25/2012 - 16:26  
    Submitted by web@researchtop... on Fri, 05/25/2012 - 16:25  
    Submitted by web@researchtop... on Fri, 05/25/2012 - 16:22  
    Submitted by web@researchtop... on Fri, 05/25/2012 - 16:21  
    Submitted by web@researchtop... on Fri, 05/25/2012 - 16:20  
    Submitted by web@researchtop... on Fri, 05/25/2012 - 16:19  
    Submitted by web@researchtop... on Fri, 05/25/2012 - 16:18  
    Submitted by web@researchtop... on Fri, 05/25/2012 - 16:15  
    Submitted by web@researchtop... on Fri, 05/25/2012 - 16:14  
    Submitted by web@researchtop... on Fri, 05/25/2012 - 15:37  
    Submitted by mphilemon@resea... on Fri, 05/25/2012 - 15:18  
  Select Publications
Bachelot T et al. TAMRAD: A GINECO randomized Phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). San Antonio Breast Cancer Symposium 2010;Abstract S1-6.